surmount-1 tirzepatide 15 mg weight loss percent reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism Relationship of early rapid weight

This means the medication is limited to situations in which the treatment of obesity outweighs the risks of the medication

Researchers at Swiss Re, a reinsurance company in Zurich, Switzerland, released estimations that GLP-1 drugs could lead to a 6.4% reduction in all-cause mortality in the U.S

The pursuit of rapid weight loss through unregulated products can delay engagement with evidence-based interventions and, in some cases, may be associated with disordered eating or body image concerns that warrant professional support

[1] [3] Simultaneously, tirzepatide suppresses glucagon secretion from pancreatic alpha cells, which decreases hepatic glucose production